Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HS269 in Advanced Solid Tumors
NCT05058352Phase 1Unknown
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS269 in solid tumor (advanced stage), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoints: Dose limiting toxicities at 33 days and Adverse Event(s) and Serious Adverse Event(s) at 12 months. Status: unknown.
02
Drugs
HS269
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05058352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058352.